Beta Bionics, Inc. (BBNX)
| Market Cap | 601.75M |
| Revenue (ttm) | 53.03M |
| Net Income (ttm) | -55.50M |
| Shares Out | 42.86M |
| EPS (ttm) | -4.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 288,978 |
| Open | 14.38 |
| Previous Close | 14.50 |
| Day's Range | 13.71 - 14.53 |
| 52-Week Range | 13.64 - 24.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.67 (+89.96%) |
| Earnings Date | May 6, 2025 |
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which co... [Read more]
Analyst Forecast
According to 6 analysts, the average rating for BBNX stock is "Strong Buy." The 12-month stock price forecast is $26.67, which is an increase of 89.96% from the latest price.
News
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to ...
Beta Bionics: A Sugar Rush For This IPO
Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company's iLet product offers a new, simplified trea...
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of it...
Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initi...
U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline
Three very small Asian issuers and one blank check company listed in the US this past week, though the biggest headlines came from a sizable launch and notable new filings. Energy equipment and servic...
Beta Bionics Aims For IPO To Cover Heavy Losses
Beta Bionics is rapidly growing revenue but faces significant operating losses with no clear path to profitability in the near term. The firm is commercializing the FDA-cleared iLet Bionic Pancreas an...
Insulin delivery device maker Beta Bionics files for a $100 million IPO
Beta Bionics, which makes an automated insulin delivery system for type 1 diabetes, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Beta Bionics Files Registration Statement for Proposed Initial Public Offering
Beta Bionics, Inc., a leader in the development of advanced diabetes management solutions, announced that it has filed a Form S-1 with the SEC....
Beta Bionics IPO Registration Document (S-1)
Beta Bionics has filed to go public with an IPO on the NASDAQ.